Orasi Medical Partners With Biogen Idec, Inc. (Massachusetts) to Use Its Novel Biomarker Technology

MINNEAPOLIS, MN--(Marketwire - April 12, 2011) - Orasi Medical® announced today that the company has entered into an agreement with Biogen Idec to test novel biomarkers in the development of treatments for central nervous system (CNS) disorders. Under the agreement, the companies will utilize the Orasi Medical technology to identify and test biomarkers based on magnetoencephalography (MEG). Non-invasive and patient friendly MEG scans will be used to assess the integrity of brain communication networks in real time and measure brain function in patients.

"We are quite pleased to partner with Biogen Idec on this innovative project," said Sarah Haecker, PhD Vice President, Business Development at Orasi Medical, "MEG-based biomarkers, will provide companies such as Biogen Idec with instruments to objectively measure drug effect and cost effective tools that better correlate with CNS disease states." Orasi Medical develops clinical neurophysiology biomarkers based on electrical activity of the brain and its products are being developed to help diagnose and track a variety of CNS diseases.

"There is a critical need for better tools to measure the effect of CNS therapeutics at all stages of clinical development," said Ajay Verma, MD, PhD Vice President Translational Neurology, at Biogen Idec. "Through the use of Orasi Index and other Orasi MEG analytical approaches we will be able to gain critical insight into the treatment effects and mechanisms of CNS compounds in our pipeline."

About Orasi Medical

Orasi Medical is a leading provider of clinical neurophysiology biomarkers and is focused on the industrialization and standardization of MEG in CNS drug and therapeutic device development. Its flagship product, Orasi Index™, supports both CNS drug effect analysis and disease template development. Orasi has the largest commercial database of MEG brain scans, biomarkers and clinical data for an expanding range of drug signatures and disease patterns. Orasi's biomarkers are being developed to help diagnosis and assess progression of CNS diseases such as Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, tinnitus, schizophrenia, and depression as well as others. For more information, please visit www.orasimedical.com.